## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.00 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (30% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($801.65)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Patient Liaison Assistance Market Is Going to Boom |McKesson Corporation â€¢ 2. Cardinal Health**
- Source: openPR.com | 20251229T145245 | Bullish | Relevance: 100%
- Worldwide Market Reports has released a new study predicting substantial growth for the "Patient Liaison Assistance Market." The report offers a comprehensive analysis of market dynamics, competitive landscape including key players like McKesson and Cardinal Health, and segmental highlights by types and applications. It also provides regional insights, research methodology, and actionable intelligence to support business growth and investment decisions.

**2. Cwm LLC Purchases 2,425 Shares of McKesson Corporation $MCK**
- Source: MarketBeat | 20251229T090839 | Bullish | Relevance: 100%
- Cwm LLC recently increased its stake in McKesson Corporation (NYSE:MCK) by 16.6%, purchasing an additional 2,425 shares in the third quarter to bring its total holdings to 17,039 shares valued at approximately $13.16 million. This move comes as McKesson has received a "Moderate Buy" consensus rating from analysts, with a target price of $892.86, following strong Q3 earnings where it surpassed EPS estimates and reported 10.2% year-over-year revenue growth. The company also announced a quarterly dividend of $0.82 per share.

**3. Here's What We Like About Cardinal Health's (NYSE:CAH) Upcoming Dividend**
- Source: Simply Wall Street | 20251228T121259 | Neutral | Relevance: 69%
- Cardinal Health (NYSE:CAH) is poised to go ex-dividend soon, offering a dividend payment of US$0.5107 per share, contributing to a 1.0% trailing yield. The company demonstrates strong dividend sustainability with a modest payout ratio of 31% from profit and 11% from free cash flow, alongside robust earnings growth of 23% per annum over the past five years. This favorable combination of rapid earnings growth, low payout ratios, and consistent dividend increases suggests Cardinal Health is a solid choice for dividend-focused investors.

**4. Louis Gerstner, who revived IBM from crisis to tech powerhouse, dies at 83**
- Source: Storyboard18 | 20251229T050001 | Neutral | Relevance: 62%
- Louis Gerstner, the former chairman and CEO of IBM, who famously led one of the most significant corporate turnarounds in modern business history, has died at 83. Gerstner took charge in 1993, steering IBM away from imminent collapse by repositioning it towards enterprise services and software, a move that substantially increased its revenue and market value. His strategic decisions and leadership transformed IBM into a tech powerhouse and his tenure is widely studied as a model of decisive management during corporate crises.

**5. One Fund Bought Up Henry Schein Stock Amid Record Quarterly Results and a New $200 Million Efficiency Plan**
- Source: The Motley Fool | 20251229T140000 | Neutral | Relevance: 61%
- Zuckerman Investment Group significantly increased its stake in Henry Schein (HSIC) by purchasing 72,040 additional shares, totaling an investment of approximately $3.38 million. This move comes as Henry Schein reported strong third-quarter results, with revenue up 5% to $3.3 billion and adjusted EBITDA rising. The company also announced a new $200 million efficiency plan and substantial share buybacks, making it an attractive long-term investment despite underperforming the broader market.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $103.3B |
| Beta | 0.38 |
| 52W Range | $565.75 - $895.58 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 18.9 |
| Current P/E | 21.5 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.8% to 1.1% (+2.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.54), confirming momentum. RSI neutral at 53. Volume at 30% of 20MA suggests lack of conviction. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.14% (CS: 65) | Neutral |
| RSI_14 | 53.4 | Neutral |
| MACD Histogram | 1.54 | Bullish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $830.15
- **Stop Loss:** $801.65 (3.4% risk)
- **Target:** $887.15 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $39,847.20
- **Portfolio %:** 39.85%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*